伊洛前列素与脓毒性休克合并内皮功能障碍成人的器官功能障碍:一项随机临床试验
这项由研究者发起的适应性、平行组、分层、双盲随机临床试验于2019年11月1日至2022年7月5日在丹麦6家医院进行,纳入279例ICU脓毒性休克合并内皮功能障碍成人,1:1随机接受伊洛前列素1 ng/kg/min(n=142)或安慰剂(n=137)静脉输注72小时。主要终点为意向性治疗人群(原文per-protocol population,实际分析278例)的ICU日均SOFA评分(校正试验 site 和基线SOFA)。伊洛前列素组日均SOFA 10.6 vs 安慰剂组10.5(校正均数差0.2,95%CI -0.8至1.2;P=.70);90天死亡率57%(81/142)vs 51%(70/136)(校正相对危险度1.12,95%CI 0.91-1.40;P=.33);严重不良事件18%(26/142)vs 15%(20/136)(校正相对危险度1.25,95%CI 0.73-2.15;P=.52)。试验在计划中期分析时因无效而终止,作者结论认为伊洛前列素不太可能改善此类患者结局。
要点
- 纳入标准为ICU脓毒性休克且血浆可溶性血栓调节蛋白>10 ng/mL的成人,伊洛前列素1 ng/kg/min静脉输注72小时。
- 主要终点日均SOFA评分:伊洛前列素组10.6 vs 安慰剂组10.5,校正均数差0.2(95%CI -0.8至1.2),P=.70,无显著差异。
- 90天死亡率:伊洛前列素组57%(81/142)vs 安慰剂组51%(70/136),校正相对危险度1.12(95%CI 0.91-1.40),P=.33。
- 严重不良事件:伊洛前列素组18%(26/142)vs 安慰剂组15%(20/136),校正相对危险度1.25(95%CI 0.73-2.15),P=.52;仅观察到1例严重不良反应。
- 试验在200例患者、随访90天的计划中期分析时因无效而终止,作者认为临床中给予伊洛前列素不太可能改善此类患者结局。
适用人群与场景
- ICU成人脓毒性休克合并内皮功能障碍(血浆可溶性血栓调节蛋白>10 ng/mL)患者。
- 研究在丹麦6家医院进行,纳入279例随机患者,其中278例纳入分析(伊洛前列素组142例,安慰剂组136例)。
诊断标准与关键阈值
- 内皮功能障碍定义:血浆可溶性血栓调节蛋白>10 ng/mL。
- 脓毒性休克诊断依据原文未具体列出。
处置流程与药物剂量
- 伊洛前列素组:伊洛前列素1 ng/kg/min静脉输注(遮盲),持续72小时。
- 安慰剂组:安慰剂静脉输注(遮盲),持续72小时。
研究设计与关键结果
- 研究设计:由研究者发起的适应性、平行组、分层、双盲随机临床试验,2019年11月1日至2022年7月5日在丹麦6家医院进行,最大样本量380例,计划在200例、随访90天时进行仅针对无效的中期分析。
- 人群:279例ICU脓毒性休克合并内皮功能障碍成人随机,278例分析(中位[IQR]年龄69[58-77]岁;171例(62%)男性)。
- 干预:1:1随机接受伊洛前列素1 ng/kg/min(n=142)或安慰剂(n=137)静脉输注72小时。
- 主要终点:ICU日均SOFA评分(校正试验 site 和基线SOFA,per-protocol人群),伊洛前列素组10.6(IQR 6.4-14.8)vs 安慰剂组10.5(IQR 5.9-15.5),校正均数差0.2(95%CI -0.8至1.2),P=.70。
- 次要终点:90天死亡率伊洛前列素组57%(81/142)vs 安慰剂组51%(70/136),校正相对危险度1.12(95%CI 0.91-1.40),P=.33。
- 安全性:7天严重不良事件伊洛前列素组18%(26/142)vs 安慰剂组15%(20/136),校正相对危险度1.25(95%CI 0.73-2.15),P=.52;仅观察到1例严重不良反应。
- 试验在计划中期分析时因无效而终止。
证据类型、等级与局限
- 证据类型:随机临床试验(适应性、平行组、分层、双盲)。
- 试验注册号:ClinicalTrials.gov NCT04123444。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在脓毒性休克合并严重内皮功能障碍的ICU成人中,伊洛前列素1 ng/kg/min输注72小时未降低日均SOFA评分,临床中给予伊洛前列素不太可能改善此类患者结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Soluble thrombomodulin is a marker of endotheliopathy, and iloprost may improve endothelial function. In patients with septic shock, high plasma levels of soluble thrombomodulin (>10 ng/mL) have been associated with worse organ dysfunction and mortality.
OBJECTIVE: To assess the effects of treatment with iloprost vs placebo on the severity of organ failure in patients with septic shock and plasma levels of soluble thrombomodulin higher than 10 ng/mL.
DESIGN, SETTING, AND PARTICIPANTS: This investigator-initiated, adaptive, parallel group, stratified, double-blind randomized clinical trial was conducted between November 1, 2019, and July 5, 2022, at 6 hospitals in Denmark. The trial had a maximum sample size of 380, with an interim analysis for futility only at 200 patients with 90 days of follow-up. In total, 279 adults in the intensive care unit (ICU) with septic shock and endotheliopathy were included.
INTERVENTIONS: Patients were randomized 1:1 to masked intravenous infusion of iloprost, 1 ng/kg/min (n = 142), or placebo (n = 137) for 72 hours.
MAIN OUTCOMES AND MEASURES: The primary outcome was mean daily Sequential Organ Failure Assessment (SOFA) score in the ICU adjusted for trial site and baseline SOFA score for the per-protocol population. SOFA scores for each of the 5 organ systems ranged from 0 to 4, with higher scores indicating more severe dysfunction (maximum score, 20). The secondary outcomes included serious adverse reactions and serious adverse events at 7 days and mortality at 90 days.
RESULTS: Of 279 randomized patients, data from 278 were analyzed (median [IQR] age, 69 [58-77] years; 171 (62%) male), 142 in the iloprost group and 136 in the placebo group. The trial was stopped for futility at the planned interim analysis. The mean [IQR] daily SOFA score was 10.6 (6.4-14.8) in the iloprost group and 10.5 (5.9-15.5) in the placebo group (adjusted mean difference, 0.2 [95% CI, -0.8 to 1.2]; P = .70). Mortality at 90 days in the iloprost group was 57% (81 of 142) vs 51% (70 of 136) in the placebo group (adjusted relative risk, 1.12 [95% CI, 0.91-1.40]; P = .33). Serious adverse events occurred in 26 of 142 patients (18%) for the iloprost group vs 20 of 136 patients (15%) for the placebo group (adjusted relative risk, 1.25 [95% CI, 0.73-2.15]; P = .52). Only 1 serious adverse reaction was observed.
CONCLUSIONS AND RELEVANCE: In this randomized clinical trial of adults in the ICU with septic shock and severe endotheliopathy, infusion of iloprost, 1 ng/kg/min, for 72 hours did not reduce mean daily SOFA scores compared with placebo. In a clinical context, administration of iloprost will be unlikely to improve outcome in these patients.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04123444.
参考来源
- Bestle MH, Stensballe J, Lange T, et al. Iloprost and Organ Dysfunction in Adults With Septic Shock and Endotheliopathy: A Randomized Clinical Trial. JAMA Netw Open. 2024. PMID: 39259541. doi:10.1001/jamanetworkopen.2024.32444
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。